Publication date: Available online 27 February 2019
Source: Journal of the American Academy of Dermatology
Author(s): Sarah Faiz, Jonathan Giovannelli, Céline Podevin, Marie Jachiet, Jean-David Bouaziz, Ziad Reguiai, Audrey Nosbaum, Audrey Lasek, Marie-Christine Ferrier le Bouedec, Aurélie Du Thanh, Nadia Raison-Peyron, Florence Tetart, Anne-Benedicte Duval-Modeste, Laurent Misery, François Aubin, Anne Dompmartin, Cécile Morice, Catherine Droitcourt, Angèle Soria, Jean-Philippe Arnault
Abstract
Background
Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials.
Objective
We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort.
Methods
Patients were included between March 2017 and April 2018. Efficacy outcomes were collected both at baseline and three months (M3), when available, including SCORAD (Scoring Atopic Dermatitis) and EASI (Eczema Area and Severity Index) scores. Adverse events (AE) were recorded at the follow-up.
Results
We included 241 patients. The median follow-up time was 3.8±3.7 months. SCORAD75 and EASI75 were achieved in 27/163 (16.6%) and 40/82 (48.8%) patients, respectively. The median SCORAD and EASI at M3 were significantly lower compared with baseline (25±21 vs 56±27.4, p<10-9 and 4.1±6.8 vs 17.9±15.4, p<10-9, respectively). Conjunctivitis was reported in 84/241 (38.2%) patients. The proportion of eosinophilia (>500/mm3) during follow-up (57%) was higher than at baseline (33.7%) (n=172, p<10-6). Dupilumab was stopped in 42 cases, 27 of which were due to an AE.
Limitations
No control group, missing data.
Conclusion
This real-life study demonstrated results similar to clinical trials, with regard to dupilumab effectiveness, but revealed a higher frequency of conjunctivitis and eosinophilia.
https://ift.tt/2GR01UH
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου